FDA Expands Use of Zoryve to Include Young Children With Plaque Psoriasis

FDA expands use of Zoryve to include young children with plaque psoriasis

The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream, 0.3%, for the topical treatment of

<![CDATA[FDA Expands Casgevy Approval to Children as Young as 2 Years With Sickle Cell Disease or Transfusion-Dependent β-Thalassemia]]>

<![CDATA[FDA Expands Wilate Approval for Routine Prophylaxis in Children Younger Than 6 With von Willebrand Disease]]>

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Conditions : Moderate-to-Severe Atopic Dermatitis Interventions : Drug: Rezpegaldesleukin; Drug: Placebo Sponsors : Nektar Therapeutics Recr

Expanded Pediatric Use for Roflumilast Under FDA Review

If approved, topical roflumilast 0.05% will be approved for treating atopic dermatitis down to age 3 months. Medscape Medical News

FDA Expands Casgevy Use to Children as Young as 2 Years Old

As reported on FiercePharma, the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Vertex Pharmaceuticals’ gen